Bayer Navigates a Legal and Strategic Crossroads as Supreme Court Decision Looms
Published on 06/23/2026 at 14:46 | Redaktion boerse-global.de
The coming days will test Bayer’s resilience on multiple fronts. All eyes are on Washington, where the US Supreme Court is set to rule in the Durnell case — a verdict that could radically reshape the company’s exposure to glyphosate litigation. The stock, which changed hands at €37.86 recently, reflects the tug-of-war between a bold internal overhaul and the lingering threat of multi-billion-dollar liabilities.
A Chapter Closes, Another Opens
Just as the Durnell ruling approaches, Bayer has finally drawn a line under a separate legal irritant. A two-year complaint under the OECD guidelines, brought by civil society groups over the sale of glyphosate and genetically modified soya in Latin America, has been formally concluded. The National Contact Point accepted parts of the complaint and offered mediation — but explicitly excluded any damages. The NGOs rejected the offer, and Bayer welcomed the end of the process. That resolution adds to a broader thaw in the company’s legal landscape, following the $7.25 billion US settlement reached in February 2026.
Yet the financial drag from American courtrooms remains immense. Estimates put Bayer’s total 2026 litigation costs at approximately €5 billion, a burden that has helped push the expected free cash flow into negative territory for the year. The new organisational model, which aims to cut bureaucracy and save €2 billion by the end of 2026, is therefore a race against time: can the operational improvements offset the cash drain?
Should investors sell immediately? Or is it worth buying Bayer?
AI Steps Into the Lab
While the legal team tackles legacy exposures, the pharmaceuticals division is turning to artificial intelligence to accelerate drug discovery. Bayer has deepened its collaboration with Iambic Therapeutics, targeting so-called small molecules for biological targets that have historically been hard to address. Iambic will receive upfront payments, plus milestone and royalty fees tied to success. The deal underscores Bayer’s strategic pivot away from expensive trial-and-error research toward data-driven development — a shift that has already shown promise with drugs like Nubeqa and Kerendia, which are helping to offset patent expiries elsewhere in the portfolio.
Patchy Trading and a Technical Floor
The financial scorecard for the first quarter of 2026 offered a mixed picture. Revenue slipped 2.4% year-on-year to €13.41 billion, while earnings per share came in at €2.81. The dividend for fiscal 2025 was a modest €0.11 per share. The stock now sits at roughly €38.50, a discount of about 23% from its 52-week high of €49.93, though it has still climbed nearly 46% over the past twelve months and a meaty 43% year-to-date. On a 30-day view, however, the shares are down 1.64%, and the year-to-date performance is essentially flat.
Chartists are watching the long-term support line at €36.33. With the current price just above the short-term moving average of €37.70, a break below that foundation could trigger a sharp sell-off. The wide trading range — the stock has rallied from a trough of €25.09 — reflects deep investor nervousness about headline risk.
What Comes Next
The Supreme Court’s Durnell ruling will be the first major catalyst. A decision in Bayer’s favour would structurally reduce legal uncertainty and could propel the share price. Then on 4 August, the second-quarter results are due, and the market will be keenly focused on what the new chief financial officer says about cash flow. If Bayer can defend its technical support level until then, the path toward the €40 mark may reopen. The next few weeks will determine whether the company’s turnaround story has the momentum to match its courtroom dramas.
Ad
Bayer Stock: New Analysis - 23 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
